Home › NDC Lookup › RxCUI directory › RxCUI 1050325

Hyoscyamine sulfate 0.12 MG / methenamine 81.6 MG / methylene blue 10.8 MG / sodium phosph... — RxCUI 1050325

RxNorm drug concept · Semantic clinical drug
RxCUI 1050325 Semantic clinical drug · SCD ● Current RxNorm concept 3 FDA products 3 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI1050325
Official nameHyoscyamine sulfate 0.12 MG / methenamine 81.6 MG / methylene blue 10.8 MG / sodium phosphate, monobasic 40.8 MG Oral Tablet
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
FDA products mapped3
Package NDCs mapped3
Reported Medicaid activity (SDUD)1,148 prescriptions · 11 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Methenamine: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • That's a great question. Methenamine isn't used to clear an active infection — it's used to prevent another one from taking hold. Once your other antibiotic has done that job, meth...
  • Why do I need to take methenamine if my infection is already gone?
  • Yes, it actually does. Methenamine only converts into its active antibacterial form in acidic urine. Foods and medications that make your urine more alkaline — less acidic — can re...
  • Does it matter what I eat or drink while I'm on this medication?
📖 Read our full Methenamine guide →

🕸️ Concept Web — How Hyoscyamine sulfate 0.12 MG / methenamine 81.6 M... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Hyoscyamine sulfate 0.12 MG / methenamine 81.6 MG / methylene blue 10.8 MG / sodium phosphate, monobasic 40.8 MG Oral Tablet RxCUI 1050325

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 6

    The active substance itself — no strength, form, or brand attached yet.

    • Hyoscyamine 153970
    • Methenamine 6832
    • Methylene blue 6878
    • Sodium phosphate, monobasic 235496
    • Hyoscyamine / methenamine / methylene blue / sodium phosphate, monobasic 1050324
    • Hyoscyamine sulfate 1225
  2. Brand names 2

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Uro-Blue 1597576
    • Urogesic Blue Reformulated Apr 2012 1251285
  3. Dose forms 17

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Hyoscyamine / methenamine / methylene blue / sodium phosphate, monobasic Oral Tablet 1050323
    • Hyoscyamine sulfate / methenamine / methylene blue / sodium phosphate, monobasic Oral Tablet 2646891
    • Hyoscyamine / methenamine / methylene blue / sodium phosphate, monobasic Oral Product 1164650
    • Hyoscyamine / methenamine / methylene blue / sodium phosphate, monobasic Pill 1164651
    • Hyoscyamine sulfate / methenamine / methylene blue / sodium phosphate, monobasic Oral Product 2659941
    • Hyoscyamine sulfate / methenamine / methylene blue / sodium phosphate, monobasic Pill 2662681
    • Hyoscyamine / methenamine / methylene blue / sodium phosphate, monobasic Oral Tablet [Uro-Blue] 1597578
    • Hyoscyamine / methenamine / methylene blue / sodium phosphate, monobasic Oral Tablet [Urogesic Blue Reformulated Apr 2012] 1251287
    • +9 more in this family
  4. Clinical & branded drugs 8

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 24 of 33 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Hyoscyamine sulfate 0.12 MG SCDC · 1037233
  • Methenamine 81.6 MG SCDC · 340422
  • Methylene blue 10.8 MG SCDC · 384913
  • Sodium phosphate, monobasic 40.8 MG SCDC · 384927
  • Hyoscyamine / methenamine / methylene blue / sodium phosphate, monobasic Oral Tablet SCDF · 1050323
  • Hyoscyamine sulfate / methenamine / methylene blue / sodium phosphate, monobasic Oral Tablet SCDFP · 2646891
  • Hyoscyamine / methenamine / methylene blue / sodium phosphate, monobasic Oral Product SCDG · 1164650
  • Hyoscyamine / methenamine / methylene blue / sodium phosphate, monobasic Pill SCDG · 1164651
  • Hyoscyamine sulfate / methenamine / methylene blue / sodium phosphate, monobasic Oral Product SCDGP · 2659941
  • Hyoscyamine sulfate / methenamine / methylene blue / sodium phosphate, monobasic Pill SCDGP · 2662681

Brand-Name Concepts

  • Hyoscyamine sulfate 0.12 MG / methenamine 81.6 MG / methylene blue 10.8 MG / sodium phosphate, monobasic 40.8 MG Oral Tablet [Urogesic Blue Reformulated Apr 2012] SBD · 1251290
  • Hyoscyamine sulfate 0.12 MG / methenamine 81.6 MG / methylene blue 10.8 MG / sodium phosphate, monobasic 40.8 MG Oral Tablet [Uro-Blue] SBD · 1597581
  • Hyoscyamine sulfate 0.12 MG / methenamine 81.6 MG / methylene blue 10.8 MG / sodium phosphate, monobasic 40.8 MG [Uro-Blue] SBDC · 1597577
  • Hyoscyamine sulfate 0.12 MG / methenamine 81.6 MG / methylene blue 10.8 MG / sodium phosphate, monobasic 40.8 MG [Urogesic Blue Reformulated Apr 2012] SBDC · 1251286
  • Hyoscyamine / methenamine / methylene blue / sodium phosphate, monobasic Oral Tablet [Uro-Blue] SBDF · 1597578
  • Hyoscyamine / methenamine / methylene blue / sodium phosphate, monobasic Oral Tablet [Urogesic Blue Reformulated Apr 2012] SBDF · 1251287
  • Hyoscyamine sulfate / methenamine / methylene blue / sodium phosphate, monobasic Oral Tablet [Uro-Blue] SBDFP · 2656465
  • Hyoscyamine sulfate / methenamine / methylene blue / sodium phosphate, monobasic Oral Tablet [Urogesic Blue Reformulated Apr 2012] SBDFP · 2657243
  • Uro-Blue Oral Product SBDG · 1597579
  • Uro-Blue Pill SBDG · 1597580

📦 FDA Products & Package NDCs

3 products · 3 package NDCs
3 package NDCs map to RxCUI 1050325 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00485-0151-01 100 TABLET, COATED in 1 BOTTLE, PLASTIC (0485-0151-01) UROGESIC BLUE EDWARDS PHARMACEUTICALS, INC. 2010-11-19
00485-0151-30 30 TABLET, COATED in 1 BOTTLE, PLASTIC (0485-0151-30) UROGESIC BLUE EDWARDS PHARMACEUTICALS, INC. 2010-11-19
58657-0454-01 100 TABLET in 1 BOTTLE (58657-454-01) Me NaPhos MB Hyo 1 Method Pharmaceuticals 2015-12-01
Observed labelers: EDWARDS PHARMACEUTICALS, INC. (2) · Method Pharmaceuticals (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.